The placebo opponent

A placebo-controlled result and a victory against another medicine answer different questions. Both deserve their own place in the record.

STEP 1

In STEP 1, semaglutide produced a mean body-weight change of −14.9% versus −2.4% with placebo at 68 weeks in adults with overweight or obesity without diabetes. The study enrolled 1,961 adults.

For this placebo comparison, I’d happily call the achievement impressive. The placebo group also had a reported weight change, which is why both sides deserve to appear in the account. The experiment gives a difference between groups rather than a solitary before-and-after figure.

That is a useful starting point for the argument here. Semaglutide can have substantial evidence of benefit against placebo while another compound produces greater mean weight loss in a direct comparison. The claims address different opponents.

Two research coordinators sorting plain sealed envelopes at a sunlit desk — An imagined research-office scene; the sealed envelopes evoke allocation by chance, without recreating a named trial.

STEP 5

STEP 5 followed adults with overweight or obesity for two years. Semaglutide produced sustained, clinically meaningful weight loss over 104 weeks, significantly greater than placebo.

The longer duration earns its place in the discussion. Time deserves a seat at this contest too. Here the observation concerns weight reduction during treatment over the studied period.

The paper supplies a longer placebo comparison. It still leaves a distinction between sustaining a benefit during treatment and retaining it after treatment ends. The result stated here concerns the former; it cannot decide the latter by itself.

The active opponent

SURMOUNT-5 used semaglutide as an active comparator for tirzepatide, with tirzepatide producing greater mean weight loss at 72 weeks. That is a different contest from the placebo-controlled STEP studies.

“Effective” earns my enthusiasm once its comparator is attached. Effective against placebo is an informative achievement. Best among competing medicines asks an additional question. The direct trial supplies an answer for its weight-loss outcome, without erasing the placebo-controlled findings.

Each result earns its place, with its opponent attached. It is less ceremonial than a coronation and considerably more useful.

See the shared-trial comparison, including its weight-change figures.